Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort.
Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort. Am J Hematol. 2026 Aug 31.
PMID: 42674730
Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial.
Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial. Blood Adv. 2026 Aug 19.
PMID: 42616616
Outcomes and Safety of CAR-T Cell Therapy in B-NHL Patients With Reduced Left Ventricular Ejection Fraction.
Outcomes and Safety of CAR-T Cell Therapy in B-NHL Patients With Reduced Left Ventricular Ejection Fraction. Transplant Cell Ther. 2026 Oct; 32(10):1240.e1-1240.e5.
PMID: 42217793
Hematopoietic Cell Transplant Access and Patient Diversity.
Hematopoietic Cell Transplant Access and Patient Diversity. JAMA Netw Open. 2026 05 01; 9(5):e2610839.
PMID: 42084866
Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.
Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026 Mar 12; 147(11):1168-1177.
PMID: 41385341
Another Feather In The Cap for Posttransplant Cyclophosphamide GVHD Prophylaxis?
Another Feather In The Cap for Posttransplant Cyclophosphamide GVHD Prophylaxis? JAMA Oncol. 2025 Nov 06.
PMID: 41196611
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies.
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies. Br J Haematol. 2026 Jan; 208(1):343-347.
PMID: 41139955
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood Adv. 2025 Jul 22; 9(14):3613-3616.
PMID: 40334078
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy.
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. EJHaem. 2025 Jun; 6(3):e70078.
PMID: 40521395
Overall cancer risk in people with deleterious germline DDX41 variants.
Overall cancer risk in people with deleterious germline DDX41 variants. Haematologica. 2025 09 01; 110(9):2076-2090.
PMID: 39945023